12:00 AM
May 21, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

FluGEM: Phase I data

A single-blind, Dutch Phase I trial in 60 healthy volunteers aged 18-49 showed that intranasal FluGEM was well tolerated with a rate of overall adverse events comparable to that of standard trivalent split influenza antigen. No...

Read the full 158 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >